Core Viewpoint - Kolunbotai Biotech-B (06990) has entered into a structured deposit agreement with Bank of China, committing to subscribe to a structured deposit amounting to RMB 440 million, which is expected to yield higher returns than typical commercial bank deposits [1] Group 1 - The structured deposit is characterized as a capital-protected financial product with floating returns, indicating a strategic move to enhance the efficiency of the company's idle funds [1] - The anticipated return rate and the short to medium-term nature of the financial product are highlighted as key factors in the decision to invest in the structured deposit [1] - The board of directors believes that the terms of the structured deposit are fair and reasonable, aligning with the overall interests of the company's shareholders [1]